文献速递乳腺癌放疗

新辅助系统治疗后前哨淋巴结阳性乳腺癌非前哨淋巴结阳性预测因素

Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy.
PubMed 文献 · Radiother Oncol · 2021-08-27

该研究纳入2001至2018年间265例接受新辅助系统治疗的cT1-3、任何N、M0乳腺癌患者,术前临床腋窝阴性并接受前哨淋巴结活检,前哨淋巴结转移阳性后行腋窝淋巴结清扫。结果显示非前哨淋巴结阳性率为62.3%,与SLN转移大小无关;多因素分析中年龄较大、临床淋巴结阳性、SLN包膜外侵犯及阳性SLN/总SLN比值较高与非前哨淋巴结阳性显著相关。

要点

  • 新辅助系统治疗后前哨淋巴结阳性患者非前哨淋巴结阳性率高达62.3%,需重视腋窝干预。
  • 年龄较大、临床淋巴结阳性、SLN包膜外侵犯及高阳性SLN比值是非前哨淋巴结阳性的显著预测因素。
  • 包膜外侵犯和高淋巴结比值是III水平腋窝阳性的独立预测因素,放疗靶区降级需谨慎。

核心结论

  • 新辅助系统治疗后前哨淋巴结阳性患者非前哨淋巴结阳性率接近初次手术后的两倍,支持对腋窝进行一定干预。
  • 若腋窝淋巴结清扫仅限于I和II水平,III水平受累率最高达31%,似乎需要额外治疗,而选择性省略需进一步研究。

研究设计与样本

  • 回顾性队列研究,从机构数据库连续纳入2001至2018年间265例接受新辅助系统治疗的cT1-3、任何N、M0乳腺癌患者。
  • 患者术前临床腋窝阴性并适合前哨淋巴结活检,前哨淋巴结转移阳性后行完成性腋窝淋巴结清扫。
  • 采用多因素逻辑回归模型分析非前哨淋巴结阳性的预测因素,并观察非前哨淋巴结在腋窝各水平的分布。

主要发现

  • 非前哨淋巴结阳性见于62.3%的病例,且与前哨淋巴结转移大小无相关性。
  • 多因素分析中与NSSN阳性显著相关的变量包括年龄较大(p=0.025)、临床淋巴结阳性(p=0.002)、SLN包膜外侵犯(p=0.001)及阳性SLN/总SLN比值较高(p=0.016)。
  • 包膜外侵犯和高淋巴结比值是III水平腋窝阳性的独立预测因素。
  • 按研究变量将患者分为中危和高危组后,三个腋窝水平的非前哨淋巴结阳性率范围为23-56%,该比率不支持放疗体积降级。
  • III水平腋窝低受累率(6.3%)通过基于腋窝淋巴结清扫后ypN状态的RAPCHEM试验标准能更好地识别。

关键数值与推荐

  • 非前哨淋巴结阳性率62.3%。
  • 多因素分析中年龄较大p=0.025,临床淋巴结阳性p=0.002,SLN包膜外侵犯p=0.001,阳性SLN/总SLN比值较高p=0.016。
  • 中危和高危组中三个腋窝水平的非前哨淋巴结阳性率范围为23-56%。
  • III水平腋窝低受累率为6.3%。

临床怎么用

  • 对于新辅助系统治疗后前哨淋巴结阳性的乳腺癌患者,应警惕非前哨淋巴结高阳性率,考虑腋窝干预的必要性。
  • 年龄较大、临床淋巴结阳性、SLN包膜外侵犯及高阳性SLN比值的患者可能更需要积极的腋窝处理。
  • 若计划仅行I和II水平腋窝淋巴结清扫,需注意III水平可能受累(最高达31%),应考虑额外治疗如放疗。
  • 放疗体积降级需谨慎,因中高危组非前哨淋巴结阳性率仍达23-56%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To assess the rate of positive non-sentinel lymph nodes (non-SLNs) after neoadjuvant systemic therapy (NAST) in breast cancer (BC) following positive sentinel lymph node biopsy (SLNB). MATERIALS AND METHODS: From institutional database, 265 consecutive patients receiving NAST for cT1-3, any N, M0 BC between 2001 and 2018 were identified. Patients presented clinically negative axilla before surgery and were candidate for SLNB. Following metastatic SLNB, completion axillary lymph node dissection (AxLND) was performed. Non-SLNs rate was investigated using multivariate (MV) logistic regression models. The distribution of non-SLNs across the axilla was observed. RESULTS: Positive non-SLNs were found in 62.3% of cases and showed no correlation with SLN metastasis size. At MV, statistically significant variables associated with non-SLNs were older age (p = 0.025), clinically positive lymph nodes (p = 0.002), SLN extracapsular extension (ECE, p = 0.001), and higher ratio of positive SLNs/total SLNs (p = 0.016). ECE and higher nodal ratio were independent predictors of III axillary level positivity. By categorizing patients in intermediate- and high-risk groups using the study variables, positive non-SLNs were found in the range of 23-56% across the three axillary levels, rates which did not support radiotherapy volume de-escalation. The III axillary level lower involvement (6.3%) was better identified with the RAPCHEM trial criteria based on the ypN status after AxLND. CONCLUSIONS: Involved non-SLNs rate following positive SLNB after NAST is nearly double the rate observed after primary surgery, supporting some intervention on the axilla. If AxLND is limited to I and II level, the involvement of the III level up to 31% of the cases seems to require some additional treatment, while the omission in selected cases needs further investigation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Leonardi MC, Arrobbio C, Gandini S, et al. Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy. Radiother Oncol. 2021. PMID: 34461184. doi:10.1016/j.radonc.2021.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。